Abeona Therapeutics Inc. (ABEO)

16.55 +0.45 (+2.795%)

IEX Real-Time Price

June 20, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 16.1

Price Open 16.1

Volume: 1.05M

Avg Volume: 1.09M

Market Cap: 782.9M

P/E Ratio -23.31

52 Wk Range 4.75-22.75



ABEO Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-05-31
45.28M
12.72M
12.51
28.09%

2018-05-15
45.28M
11.62M
13.05
25.67%

2018-04-30
45.21M
11.49M
9.95
25.41%

2018-04-13
45.21M
11.55M
11.35
25.55%




ABEO Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-21
Q1 2018
N/A
-0.19 (3)
0.00
0.00

2018-03-30
Q4 2017
N/A
-0.13 (3)
0.00
0.00

2018-03-16
Q4 2017
N/A
-0.13 (3)
-0.19
-0.06

2017-11-15
Q3 2017
N/A
-0.18 (3)
-0.13
0.05

News

Gene therapy players in the green (2018-06-20 14:27 SeekingAlpha)

Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo…

 


Statistics

Shares Outstanding: 47.31M

Top 15 Institution Percent: 66.60

Price To Sales: 231.50

Price To Book: 4.45

Revenue: 436000

Gross Profit: N/A

Cash: 114.83M

Debt: N/A

Return On Assets: -20.53

Return On Equity: -21.81

Profit Margin: N/A

Price History

Beta: 2.25

50-day Moving Avg: 18.03

200-day Moving Avg: 16.18

YTD Change: -6.40

5-day Change: 0.00

1-month Change: 0.47

3-month Change: 15.21

6-month Change: 5.06

1-year Change: N/A

Revenue Per Share: 0.00

Revenue Per Employee: 10381.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Abeona Therapeutics Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.abeonatherapeutics.com

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.